Undervalued Small Caps With Insider Activity To Explore In October 2024

In This Article:

As global markets navigate a complex landscape marked by record highs in major U.S. indices and modestly higher-than-expected inflation, small-cap stocks present intriguing opportunities for investors seeking growth potential amid broader market dynamics. In this environment, understanding what constitutes a promising investment involves evaluating companies with solid fundamentals and strategic insider activity that may indicate confidence in future prospects.

Top 10 Undervalued Small Caps With Insider Buying

Name

PE

PS

Discount to Fair Value

Value Rating

Trican Well Service

7.3x

0.9x

18.26%

★★★★★☆

Nexus Industrial REIT

3.7x

3.6x

18.08%

★★★★☆☆

PSC

8.0x

0.4x

40.39%

★★★★☆☆

Citizens & Northern

13.0x

2.9x

42.48%

★★★★☆☆

Rogers Sugar

15.7x

0.6x

47.26%

★★★★☆☆

Primaris Real Estate Investment Trust

12.7x

3.4x

45.18%

★★★★☆☆

Calfrac Well Services

2.5x

0.2x

17.65%

★★★★☆☆

Sagicor Financial

1.3x

0.3x

-43.36%

★★★★☆☆

Marlowe

NA

0.7x

41.17%

★★★★☆☆

Community West Bancshares

18.7x

2.9x

42.25%

★★★☆☆☆

Click here to see the full list of 191 stocks from our Undervalued Small Caps With Insider Buying screener.

Let's explore several standout options from the results in the screener.

Phibro Animal Health

Simply Wall St Value Rating: ★★★★★☆

Overview: Phibro Animal Health is a company that specializes in providing animal health and mineral nutrition products, with a market capitalization of approximately $0.74 billion.

Operations: The company generates revenue primarily from Animal Health, Mineral Nutrition, and Performance Products segments. Over recent periods, the gross profit margin has shown a trend around 30.80%, with notable fluctuations in net income margins reflecting varying profitability levels. Operating expenses and cost of goods sold significantly impact overall financial performance.

PE: 407.2x

Phibro Animal Health, a smaller company in the animal health sector, recently projected net sales between US$1.04 billion and US$1.09 billion for fiscal 2025, with expected growth driven by its Animal Health segment. Despite a challenging year with net income dropping to US$2.42 million from US$32.61 million previously, insider confidence is evident through recent share purchases by key executives this year. The company's strategic focus on recovery in Mineral Nutrition and Performance Products segments suggests potential future growth opportunities within its industry context.

NasdaqGM:PAHC Share price vs Value as at Oct 2024
NasdaqGM:PAHC Share price vs Value as at Oct 2024

MaxLinear

Simply Wall St Value Rating: ★★★★☆☆